ETOPOSIDE
Burkitt's Leukemia
Nicola GoekbugetSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Burkitt's Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Nicola Goekbuget | Phase 4 | BB |
VINDESINE Nicola Goekbuget | Phase 4 | BB |
Ifosfamide Nicola Goekbuget | Phase 4 | BB |
Inno-206 Nicola Goekbuget | Phase 4 | BB |
METHOTREXATE Nicola Goekbuget | Phase 4 | BB |
View all 11 →
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →